

# FOR IMMEDIATE RELEASE

---



**Media Contact:**

[info@latticebiologics.com](mailto:info@latticebiologics.com)

Lattice Biologics Ltd.

(TSX-V: LBL) (OTCQB: LBLTF)

16701 N 90th Street, Suite#101

Scottsdale, AZ 85260

480-563-0800 Office

[News@LatticeBiologics.com](mailto:News@LatticeBiologics.com)

[www.LatticeBiologics.com](http://www.LatticeBiologics.com)



Guy Cook, CEO,  
Lattice Biologics Ltd.



Cheryl Farmer, CFO,  
Lattice Biologics Ltd.

[Subscribe to Lattice News Updates](#)

Follow us on Twitter: [@LatticeBio](#)

---

## NEWS RELEASE

### LATTICE BIOLOGICS UPGRADED TO OTCQB VENTURE MARKET

**February 1, 2017 - Scottsdale, AZ - Lattice Biologics Ltd.** ([TSX-V: LBL](#)) ([OTCQB: LBLTF](#)) ("Lattice Biologics" or the "Company") is pleased to announce that the Company has been approved to upgrade its common shares from the Pink Open Market to the OTCQB® Venture Market under the trading symbol "LBLTF", effective January 31, 2017.

CEO Guy Cook commented, "Upgrading to the OTCQB is a very positive step forward for the Company. The upgrade confirms our commitment to our growing United States shareholder base and will improve the trading experience for investors."

**About OTCQB®:**

The OTCQB® Venture Market, operated by OTC Markets Group Inc., requires companies to remain current and compliant in their reporting, and undergo an annual verification and management certification process. These standards provide improved investor confidence through verified information, as well as greater information availability, and transparent prices for investors with Real Time Level 2 quotes.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for Lattice Biologics at <http://www.otcm Markets.com/stock/LBLTF/quote>.

Lattice Biologics Ltd.

Guy Cook,  
Chief Executive Officer  
Telephone No: (480) 563-0800

---

### **About Lattice Biologics Ltd.:**

Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.

### **Versatile allografts for a variety of surgical applications:**

- Enhancing fusion in spine surgery
- Enhancing breast reconstruction post mastectomy for breast cancer patients
- Sports medicine indications, including ACL repair
- Promotion of bone regeneration in foot and ankle surgery
- Promotion of cranial healing following neurosurgery
- Enhancing wound repair in burn victims
- Subchondral bone defect repair in knee and other joint surgeries

### **The Company is currently exploring new technologies in regenerative and personalized medicine:**

- **All natural amniotic fluid supplement for arthritic joints**
  - [Demonstrates lasting pain relief and improved outcomes in the largest clinical study of its kind](#)
- **[Personalized Cancer Diagnostics](#) - revolutionary high-throughput precision chemotherapy screening**
  - [See study details](#)

Lattice Biologics operates headquarters, laboratory and manufacturing facilities in Scottsdale, Arizona as well as offices in Toronto Ontario. The Company maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.

Lattice Biologics ([TSX-V: LBL](#)) ([OTCOB: LBLTF](#)) became a publicly traded company on January 4, 2016.

---

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### **Cautionary Statement on Forward-Looking Information:**

*Certain information contained in this news release constitutes "forward-looking statements" within the meaning of the 'safe harbour' provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "potential", "future", "expected", "could", "possible", "goal", "intends", "will" or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company's strategy, plans, or future financial performance, such as statements with respect to future revenues or products, and other statements that express*

*management's expectations or estimates of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.*

*Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.*

**Subscribe to Lattice News Updates**

**Follow us on Twitter: [@LatticeBio](#)**

# # #